公开(公告)号：US20250082869A1

公开(公告)日：2025-03-13

申请号：US18726062

申请日：2022-11-07

Applicant: CANSINO BIOLOGICS INC. ,  STAMFORD DEVICES LIMITED

Inventor： Weixue SI ,  Xiaolong ZHAO ,  Yueran WANG ,  Yueying JIANG ,  Liping WANG ,  Xuefeng YU ,  Shoubai CHAO ,  Tao ZHU

IPC: A61M11/00

Abstract: Disclosed are a nebulization cup and application in nebulized inhalation administration thereof, and especially application in nebulized inhalation administration of a preventive and/or therapeutic drug for a respiratory disease (such as SARS-CoV-2 vaccine). After adding an antistatic agent, the nebulization cup can effectively maintain the stability of drug mist within a certain period of time, with stable particle size, less drug residue in the cup, thus ensuring effective inhalable amount, and the administration operation is simple and convenient, thus the nebulization cup can significantly improve the inoculation efficiency and can be used for large-scale inoculation.

公开(公告)号：US20230111095A1

公开(公告)日：2023-04-13

申请号：US17769607

申请日：2020-09-25

Applicant: Cansino Biologics Inc.

Inventor： Haomeng WANG ,  Qiaoling YAN ,  Shoubai CHAO ,  Huhua MAO ,  Tao ZHU

IPC: A61K39/385 ,  A61P31/04 ,  A61K39/09

Abstract: The present invention relates to a carrier protein with site-directed mutation and use thereof in preparation of a vaccine, wherein the carrier protein is selected from fusion proteins formed by one, two or more of diphtheria toxoid, a non-toxic mutant of diphtheria toxin, a bacterial outer membrane protein and a bacterially expressed protein, wherein an amino acid at at least one site on the carrier protein is mutated into an unnatural amino acid, and the unnatural amino acid contains an azido or alkynyl terminal group. In a mutual reaction process of the carrier protein with site-directed mutation of the present invention and a polysaccharide antigen, a covalent bond is formed, and meanwhile a formed conjugate is in a bead-string state, so that the carrier protein and the polysaccharide antigen can be effectively prevented from being excessively crosslinked. Further, particle size distribution of the conjugate is significantly uniform and controllable, which provides an effective means for improving quality of a polysaccharide-protein conjugate vaccine.

公开(公告)号：US20230313225A1

公开(公告)日：2023-10-05

申请号：US18011742

申请日：2021-11-08

Applicant: CANSINO BIOLOGICS INC.

Inventor： Meng XIAO ,  Yunjie LIU ,  Tao ZHU ,  Yunli XU ,  Can XU ,  Junqiang LI ,  Shoubai CHAO

IPC: C12N15/86 ,  C12M1/00 ,  A61K39/215

CPC classification number: C12N15/86 ,  C12M29/10 ,  A61K39/215 ,  C12N2710/10334 ,  C12N2710/10343 ,  C12N2710/10352 ,  C12N2710/10362 ,  C12N2500/32 ,  A61K2039/5256

Abstract: Provided is a method for preparing an adenovirus vector vaccine by means of a perfusion culture process. The method comprises a step of culturing adenovirus host cells, and in particular a step of adjusting the perfusion rate by means of at least two stages according to cell density. The method increases the single cell yield of a virus after infection and the specific activity of a virus harvest liquid while achieving high-density growth of adenovirus host cells.

公开(公告)号：US20230173058A1

公开(公告)日：2023-06-08

申请号：US17922328

申请日：2021-04-01

Applicant: CANSINO BIOLOGICS INC. ,  ACADEMY OF MILITARY MEDICAL SCIENCES, PLA

Inventor： Junqiang LI ,  Weixue SI ,  Tao ZHU ,  Yunli XU ,  Jie DENG ,  Shoubai CHAO

IPC: A61K39/215 ,  A61K47/42 ,  A61K47/26 ,  A61P31/14

CPC classification number: A61K39/215 ,  A61K47/42 ,  A61K47/26 ,  A61P31/14 ,  A61K2039/5256

Abstract: Disclosed is a SARS-CoV-2 vaccine, wherein the S protein of SARS-CoV-2 serves as the antigen, and the vaccine comprises an adenoviral vector, and the vaccine induces an improved protective immune response through mucosal immunity, thus preventing SARS-CoV-2 infection. Specifically, when atomized by an appropriate apparatus, the vaccine generates particles of improved uniformity, which can reach the lungs after being inhaled via the nasal cavity or the oral cavity, thus producing a protective immune response with respect to the entire respiratory tract and the lungs, enhancing the effective utilization rate of the vaccine, and increasing the effect of the vaccine.

公开(公告)号：US20220088186A1

公开(公告)日：2022-03-24

申请号：US17420608

申请日：2020-01-07

Applicant: CANSINO BIOLOGICS INC .

Inventor： Tao ZHU ,  Junqiang LI ,  Shoubai CHAO ,  Chunlin XIN ,  Wei MIAO ,  Xishan LU

IPC: A61K39/25 ,  A61K39/15 ,  A61K39/12 ,  A61K39/39 ,  A61K39/00 ,  A61P31/22

Abstract: Disclosed is an SamRNA vaccine, including a recombinant viral vector which includes: i) a viral gene replication complex including nucleotide sequences encoding viral gene replication-related proteins nsP1, nsP2, nsP3, and nsP4; and ii) a nucleotide sequence encoding at least one antigen. According to the SamRNA vaccine of the present invention, in addition to that a promoter of a modified adenoviral vector itself can transcribe an antigen gene to form mRNA, the viral gene replication-related proteins nsP1-4 use RNA as a template to synthesize a large amount of mRNAs, and the immune effect of a target antigen is greatly improved.